Brief: Repligen To Acquire Biolife Solutions, Expanding Its Cell Therapy Capabilities With Market Leading Biopreservation Media

BioLife Solutions

22/07/2026 11:57

July 22 (Reuters) - BioLife Solutions Inc BLFS.O:
REPLIGEN TO ACQUIRE BIOLIFE SOLUTIONS, EXPANDING ITS CELL THERAPY CAPABILITIES WITH MARKET LEADING BIOPRESERVATION MEDIA
BIOLIFE SOLUTIONS - REPLIGEN TO BUY BIOLIFE FOR $1.50 BILLION ENTERPRISE VALUE, 64% STOCK, 36% CASH
BIOLIFE SOLUTIONS - STOCKHOLDERS TO RECEIVE $31 PER SHARE IN CASH AND REPLIGEN STOCK
BIOLIFE SOLUTIONS - DEAL EXPECTED TO BE ACCRETIVE TO REPLIGEN'S ADJUSTED EPS BY $0.05 IN YEAR ONE, $0.25 IN YEAR TWO
BIOLIFE SOLUTIONS - STOCKHOLDERS TO RECEIVE $11.25 CASH AND 0.1442 REPLIGEN SHARES PER BIOLIFE SHARE
BIOLIFE SOLUTIONS - REPLIGEN EXPECTS AT LEAST $20 MILLION SYNERGIES IN YEAR ONE, $30 MILLION IN YEAR TWO
BIOLIFE SOLUTIONS - EXPECTS PRELIMINARY Q2 REVENUE OF $28.50 MILLION, UP 21% FROM Q2 2025
BIOLIFE SOLUTIONS - REPLIGEN PRELIMINARY Q2 REPORTED REVENUE GROWTH 12%, ORGANIC REVENUE GROWTH 13%
BIOLIFE SOLUTIONS - PRELIMINARY Q2 REVENUE GROWTH 21% YEAR-OVER-YEAR
Source text: ID:nGNXbFRqpW
Further company coverage: BLFS.O

 ((Reuters.Briefs@thomsonreuters.com;))